Lucida Medical develops AI software for radiologists to detect cancer using MRI. Pi™, their CE-marked medical device, aids in prostate cancer diagnosis in Europe and the UK, pending FDA approval for the USA. They welcome investors and healthcare professionals for research, clinical studies, and Pi™ usage. Exhibiting at major conferences like RSNA and ESUR, they present advancements in cancer detection technology. Collaborating with institutions like the University of Cambridge and Hampshire Hospitals, Lucida Medical extends Pi™ to multiple clinical indications, enhancing precision medicine. Recent studies show Pi™'s accuracy in routine NHS diagnostic pathways, promising improved cancer detection and diagnosis using AI and MRI.